Stonepine Capital Management LLC Purchases Shares of 20,400 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Stonepine Capital Management LLC acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 20,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,128,000. ANI Pharmaceuticals makes up approximately 0.9% of Stonepine Capital Management LLC’s portfolio, making the stock its 28th biggest holding.

Several other large investors have also modified their holdings of the stock. US Bancorp DE raised its holdings in shares of ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after acquiring an additional 531 shares in the last quarter. KBC Group NV lifted its position in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at approximately $166,000. Rafferty Asset Management LLC acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at approximately $200,000. Finally, Bridgefront Capital LLC acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at approximately $204,000. 76.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price objective on the stock. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Truist Financial lifted their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a report on Monday, April 21st. Finally, StockNews.com lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $80.13.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $59.99 on Friday. The company has a market cap of $1.31 billion, a P/E ratio of -109.07 and a beta of 0.56. The business has a 50-day moving average price of $66.91 and a two-hundred day moving average price of $60.77. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.33. The business had revenue of $197.12 million for the quarter, compared to analysts’ expectations of $179.75 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm’s revenue for the quarter was up 43.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.82 EPS. As a group, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. The trade was a 0.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the sale, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This represents a 1.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,681 shares of company stock worth $468,698. Corporate insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.